Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;30(7):834-9.
doi: 10.1093/eurheartj/ehn567. Epub 2008 Dec 24.

Development of life-expectancy tables for people with type 2 diabetes

Jose Leal  1 , Alastair M Gray, Philip M Clarke
Affiliations

Development of life-expectancy tables for people with type 2 diabetes

Jose Leal et al. Eur Heart J. 2009 Apr.

Abstract

Aims: To develop tables that report the life expectancy associated with levels of major modifiable risk factors for patients with type 2 diabetes.

Methods and results: A set of tables reporting life-expectancy stratified by age-sex groups for combinations of modifiable risk was constructed based on predictions from the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model. This model is based on a system of parametric proportional hazards risk equations for estimating mortality and vascular complications of diabetes that have been estimated from 3642 patients from the UKPDS. The tables show substantial potential gains in life expectancy within every age group from modifying major risk factors. The estimated life expectancy of men at age of 55 years with type 2 diabetes, 5 years after diagnosis, varies between 13.2 years for a patient who smokes, has systolic blood pressure of 180 mmHg, a total:HDL cholesterol ratio of 8, and HbA(1c) of 10%, and 21.1 years for a non-smoker with SBP of 120 mmHg, total/HDL ratio of 4, and HbA(1c) of 6%.

Conclusion: Life expectancy tables provide a potentially useful tool of conveying prognostic information to people with type 2 diabetes and suggest substantial scope for increasing longevity by improving modifiable risk factors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Assessment of life expectancy in men and women with Type 2 diabetes. These men and women were assumed to have no previous diabetes-related complications, diagnosed with the disease 5 years previously, and a body mass index of 30 and 33 kg/m2, respectively.
See this image and copyright information in PMC

References

    1. Laakso M. Hyperglycemia and cardiovascular disease in Type 2 diabetes. Diabetes. 1999;48:937–942. - PubMed
    1. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999;159:1873–1880. - PubMed
    1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016. - PubMed
    1. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840. - PubMed
    1. Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA. 2004;291:2359–2366. - PubMed

Publication types